{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:28:56Z","timestamp":1792639736992,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["00849I221"],"award-info":[{"award-number":["00849I221"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Common Good Prince Charles Hospital Foundation","award":["NI2020-61"],"award-info":[{"award-number":["NI2020-61"]}]},{"DOI":"10.13039\/501100000973","name":"Cystic Fibrosis Australia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000973","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pseudomonas aeruginosa is a multidrug-resistant pathogen causing recalcitrant pulmonary infections in people with cystic fibrosis (pwCF). Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been developed that partially correct the defective chloride channel driving disease. Despite the many clinical benefits, studies in adults have demonstrated that while P. aeruginosa sputum load decreases, chronic infection persists. Here, we investigate how P. aeruginosa in pwCF may change in the altered lung environment after CFTR modulation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>P. aeruginosa strains (n = 105) were isolated from the sputum of 11 chronically colonized pwCF at baseline and up to 21 months posttreatment with elexacaftor-tezacaftor-ivacaftor or tezacaftor-ivacaftor. Phenotypic characterization and comparative genomics were performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Clonal lineages of P. aeruginosa persisted after therapy, with no evidence of displacement by alternative strains. We identified commonly mutated genes among patient isolates that may be positively selected for in the CFTR-modulated lung. However, classic chronic P. aeruginosa phenotypes such as mucoid morphology were sustained, and isolates remained just as resistant to clinically relevant antibiotics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite the clinical benefits of CFTR modulators, clonal lineages of P. aeruginosa persist that may prove just as difficult to manage in the future, especially in pwCF with advanced lung disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiae051","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T19:35:18Z","timestamp":1709667318000},"page":"e536-e547","source":"Crossref","is-referenced-by-count":54,"title":["Impact of CFTR Modulation on <i>Pseudomonas aeruginosa<\/i> Infection in People With Cystic Fibrosis"],"prefix":"10.1093","volume":"230","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-5252","authenticated-orcid":false,"given":"Emma L","family":"Ledger","sequence":"first","affiliation":[{"name":"Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J","family":"Smith","sequence":"additional","affiliation":[{"name":"Northside Clinical Unit, The University of Queensland, Brisbane, Australia"},{"name":"Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-8901","authenticated-orcid":false,"given":"Jing Jie","family":"Teh","sequence":"additional","affiliation":[{"name":"Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle E","family":"Wood","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Page E","family":"Whibley","sequence":"additional","affiliation":[{"name":"Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9257-9133","authenticated-orcid":false,"given":"Mark","family":"Morrison","sequence":"additional","affiliation":[{"name":"Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia"},{"name":"Australian Infectious Diseases Research Centre , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna B","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pulmonary, Asthma, Cystic Fibrosis, and Sleep, Emory University School of Medicine , Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Reid","sequence":"additional","affiliation":[{"name":"Northside Clinical Unit, The University of Queensland, Brisbane, Australia"},{"name":"Australian Infectious Diseases Research Centre , Brisbane , Australia"},{"name":"QIMR Berghofer Medical Research Institute , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-5404","authenticated-orcid":false,"given":"Timothy J","family":"Wells","sequence":"additional","affiliation":[{"name":"Frazer Institute, Faculty of Medicine, The University of Queensland, Brisbane, Australia"},{"name":"Australian Infectious Diseases Research Centre , Brisbane , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"2024092316155134400_jiae051-B1","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet"},{"key":"2024092316155134400_jiae051-B2","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1073\/pnas.0602138103","article-title":"Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients","volume":"103","author":"Smith","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024092316155134400_jiae051-B3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/cid\/ciu385","article-title":"Pseudomonas aeruginosa phenotypes associated with eradication failure in children with cystic fibrosis","volume":"59","author":"Mayer-Hamblett","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024092316155134400_jiae051-B4","doi-asserted-by":"crossref","first-page":"e1003741","DOI":"10.1371\/journal.pgen.1003741","article-title":"Genome analysis of a transmissible lineage of Pseudomonas aeruginosa reveals pathoadaptive mutations and distinct evolutionary paths of hypermutators","volume":"9","author":"Marvig","year":"2013","journal-title":"PLoS Genet"},{"key":"2024092316155134400_jiae051-B5","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1183\/09031936.00060512","article-title":"Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres","volume":"41","author":"Kidd","year":"2013","journal-title":"Eur Respir J"},{"key":"2024092316155134400_jiae051-B6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12890-017-0482-7","article-title":"Antibiotic perturbation of mixed-strain Pseudomonas aeruginosa infection in patients with cystic fibrosis","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2024092316155134400_jiae051-B7","first-page":"e000167","article-title":"Transmission and lineage displacement drive rapid population genomic flux in cystic fibrosis airway infections of a Pseudomonas aeruginosa epidemic strain","volume":"4","author":"Williams","year":"2018","journal-title":"Microb Genom"},{"key":"2024092316155134400_jiae051-B8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ppul.2009","article-title":"Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition","volume":"32","author":"Kosorok","year":"2003","journal-title":"Pediatr Pulm"},{"key":"2024092316155134400_jiae051-B9","volume-title":"Australian Cystic Fibrosis Data Registry: annual report 2021","author":"Ahern","year":"2022"},{"key":"2024092316155134400_jiae051-B10","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"2024092316155134400_jiae051-B11","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"2024092316155134400_jiae051-B12","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ppul.26261","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis","volume":"58","author":"Sheikh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024092316155134400_jiae051-B13","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024092316155134400_jiae051-B14","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1002\/ppul.26485","article-title":"Impact of elexacaftor-tezacaftor-ivacaftor on lung disease in cystic fibrosis","volume":"58","author":"Gushue","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2024092316155134400_jiae051-B15","doi-asserted-by":"crossref","first-page":"e167957","DOI":"10.1172\/JCI167957","article-title":"Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist","volume":"133","author":"Nichols","year":"2023","journal-title":"J Clin Invest"},{"key":"2024092316155134400_jiae051-B16","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1164\/rccm.201609-1954OC","article-title":"Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections","volume":"195","author":"Hisert","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2024092316155134400_jiae051-B17","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.jcf.2021.11.003","article-title":"A restructuring of microbiome niche space is associated with elexacaftor-tezacaftor-ivacaftor therapy in the cystic fibrosis lung","volume":"21","author":"Sosinski","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2024092316155134400_jiae051-B18","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1569-1993(11)60011-8","article-title":"Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report","volume":"10","author":"Pressler","year":"2011","journal-title":"J Cyst Fibros"},{"key":"2024092316155134400_jiae051-B19","doi-asserted-by":"crossref","first-page":"124","DOI":"10.12688\/wellcomeopenres.14826.1","article-title":"Open-access bacterial population genomics: BIGSdb software, the PubMLST.org website and their applications","volume":"3","author":"Jolley","year":"2018","journal-title":"Wellcome Open Res"},{"key":"2024092316155134400_jiae051-B20","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1128\/JCM.00349-16","article-title":"Application of whole-genome sequencing data for O-specific antigen analysis and in silico serotyping of Pseudomonas aeruginosa isolates","volume":"54","author":"Thrane","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2024092316155134400_jiae051-B21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/35023079","article-title":"Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen","volume":"406","author":"Stover","year":"2000","journal-title":"Nature"},{"key":"2024092316155134400_jiae051-B22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ng.3148","article-title":"Convergent evolution and adaptation of Pseudomonas aeruginosa within patients with cystic fibrosis","volume":"47","author":"Marvig","year":"2015","journal-title":"Nat Genet"},{"key":"2024092316155134400_jiae051-B23","doi-asserted-by":"crossref","first-page":"e1004651","DOI":"10.1371\/journal.pgen.1004651","article-title":"Coexistence and within-host evolution of diversified lineages of hypermutable Pseudomonas aeruginosa in long-term cystic fibrosis infections","volume":"10","author":"Feliziani","year":"2014","journal-title":"PLoS Genet"},{"key":"2024092316155134400_jiae051-B24","doi-asserted-by":"crossref","first-page":"28732","DOI":"10.1038\/srep28732","article-title":"Bacterial evolution in PCD and CF patients follows the same mutational steps","volume":"6","author":"Sommer","year":"2016","journal-title":"Sci Rep"},{"key":"2024092316155134400_jiae051-B25","doi-asserted-by":"crossref","first-page":"000286","DOI":"10.1099\/acmi.0.000286","article-title":"Sequence diversity of the Pseudomonas aeruginosa population in loci that undergo microevolution in cystic fibrosis airways","volume":"3","author":"Fischer","year":"2021","journal-title":"Access Microbiol"},{"key":"2024092316155134400_jiae051-B26","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cmi.2022.01.017","article-title":"Persistence and genetic adaptation of Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease","volume":"28","author":"Ekl\u00f6f","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2024092316155134400_jiae051-B27","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1038\/s41598-017-05621-5","article-title":"Evolution of the Pseudomonas aeruginosa mutational resistome in an international cystic fibrosis clone","volume":"7","author":"L\u00f3pez-Causap\u00e9","year":"2017","journal-title":"Sci Rep"},{"key":"2024092316155134400_jiae051-B28","doi-asserted-by":"crossref","first-page":"e02142","DOI":"10.1128\/AAC.02142-19","article-title":"Hypermutator Pseudomonas aeruginosa exploits multiple genetic pathways to develop multidrug resistance during long-term infections in the airways of cystic fibrosis patients","volume":"64","author":"Colque","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092316155134400_jiae051-B29","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1128\/AAC.02676-15","article-title":"Evolution of Pseudomonas aeruginosa antimicrobial resistance and fitness under low and high mutation rates","volume":"60","author":"Cabot","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2024092316155134400_jiae051-B30","doi-asserted-by":"crossref","first-page":"943346","DOI":"10.3389\/fcimb.2022.943346","article-title":"The role of the Pseudomonas aeruginosa hypermutator phenotype on the shift from acute to chronic virulence during respiratory infection","volume":"12","author":"Hall","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2024092316155134400_jiae051-B31","doi-asserted-by":"crossref","first-page":"D646","DOI":"10.1093\/nar\/gkv1227","article-title":"Enhanced annotations and features for comparing thousands of Pseudomonas genomes in the Pseudomonas genome database","volume":"44","author":"Winsor","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"2024092316155134400_jiae051-B32","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0022-3476(05)82653-8","article-title":"Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa","volume":"116","author":"Kerem","year":"1990","journal-title":"J Pediatr"},{"key":"2024092316155134400_jiae051-B33","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2024092316155134400_jiae051-B34","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor-Ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N Engl J Med"},{"key":"2024092316155134400_jiae051-B35","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N Engl J Med"},{"key":"2024092316155134400_jiae051-B36","doi-asserted-by":"crossref","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur Respir J"},{"key":"2024092316155134400_jiae051-B37","doi-asserted-by":"crossref","first-page":"e0145422","DOI":"10.1128\/spectrum.01454-22","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on the cystic fibrosis airway microbial metagenome","volume":"10","author":"Pallenberg","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2024092316155134400_jiae051-B38","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3390\/ph15050606","article-title":"Elexacaftor-tezacaftor-ivacaftor as a final frontier in the treatment of cystic fibrosis: definition of the clinical and microbiological implications in a case-control study","volume":"15","author":"Migliorisi","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2024092316155134400_jiae051-B39","doi-asserted-by":"crossref","first-page":"e15756","DOI":"10.1016\/j.heliyon.2023.e15756","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment improves systemic infection parameters and Pseudomonas aeruginosa colonization rate in patients with cystic fibrosis a monocentric observational study","volume":"9","author":"Schnell","year":"2023","journal-title":"Heliyon"},{"key":"2024092316155134400_jiae051-B40","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmi.2019.06.011","article-title":"Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients","volume":"26","author":"Ekl\u00f6f","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2024092316155134400_jiae051-B41","first-page":"1602","article-title":"A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis","volume":"12","author":"Finch","year":"2015","journal-title":"Ann Am Thorac Soc"},{"key":"2024092316155134400_jiae051-B42","doi-asserted-by":"crossref","first-page":"108782","DOI":"10.1016\/j.celrep.2021.108782","article-title":"Pseudomonas aeruginosa aggregates in cystic fibrosis sputum produce exopolysaccharides that likely impede current therapies","volume":"34","author":"Jennings","year":"2021","journal-title":"Cell Rep"},{"key":"2024092316155134400_jiae051-B43","doi-asserted-by":"crossref","first-page":"e03109-23","DOI":"10.1128\/mbio.03109-23","article-title":"The role of hypermutation and collateral sensitivity in antimicrobial resistance diversity of Pseudomonas aeruginosa populations in cystic fibrosis lung infection","volume":"2","author":"Vanderwoude","year":"2024","journal-title":"mBio"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae051\/56844606\/jiae051.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/3\/e536\/59248551\/jiae051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/230\/3\/e536\/59248551\/jiae051.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T16:16:16Z","timestamp":1727108176000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/230\/3\/e536\/7619464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,5]]},"published-print":{"date-parts":[[2024,9,23]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae051","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9,15]]},"published":{"date-parts":[[2024,3,5]]}}}